Janet Hopkins
Chief Tech/Sci/R&D Officer chez AURA BIOSCIENCES, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Janet Jill Hopkins is currently the Director at Gyroscope Therapeutics Holdings Plc and the Chief Medical Officer at Aura Biosciences, Inc. She previously served as the Chief Executive Officer at Gyroscope Therapeutics Ltd.
and the SVP & Global Head-Ophthalmology at Novartis AG.
Hopkins holds a doctorate degree from McMaster University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0,33% | 01/02/2024 | 163 515 ( 0,33% ) | 1 M $ | 31/03/2024 |
Postes actifs de Janet Hopkins
| Sociétés | Poste | Début |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 17/02/2022 |
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 16/10/2023 |
Anciens postes connus de Janet Hopkins
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 01/10/2023 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 01/10/2023 |
Formation de Janet Hopkins
| McMaster University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
